FDA Drops Guide for Super-Antibodies Keeping Pets Safe and Sound
Published Date: 9/18/2026
Notice
Summary
The FDA just released a draft guide to help vets and companies test the safety of special animal medicines called veterinary monoclonal antibodies. This new guide aims to make safety testing easier and more consistent worldwide, helping get these medicines to animals faster and safer. If you’re involved in making or testing these products, send your feedback by November 17, 2026, to shape the final rules!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Harmonized Safety Tests for Animal mAbs
The FDA posted draft guidance GFI #298 (VICH GL62) to harmonize how safety testing is done for veterinary monoclonal antibody products (VMAPs). The guidance is for VMAPs intended for companion animals and livestock and says harmonized methods should make testing easier and more consistent worldwide and help get these medicines to animals faster and safer. The draft is open for comment through November 17, 2026.
No New Paperwork Burden From Guidance
The draft guidance says it contains no new collection of information but refers to previously approved FDA collections under OMB control numbers 0910-0032 and 0910-0117. That means the guidance itself does not add new federal paperwork requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-19181, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide to help medical device makers submit their big approval applications electronically. This new template aims to make submissions easier, faster, and more consistent for companies working with the FDA’s device and biologics centers. If you’re in the medical device game, check it out and send your feedback by November 17, 2026—no fees or changes yet, just a heads-up for smoother future filings!
2026-19166, Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.
2026-19074, Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices
The FDA has decided NOT to exempt certain radiology computer software devices from premarket review, meaning these devices still need FDA approval before hitting the market. This affects companies making cancer detection and medical image analysis software, keeping safety checks in place. The rule takes effect on September 17, 2026, so businesses should plan accordingly to avoid delays or extra costs.
Previous / Next Documents
Previous: 2026-19140, Notice of Final Federal Agency Actions on Proposed Highway in Georgia
Georgia is getting a big upgrade on I-75 with new commercial vehicle lanes stretching about 41 miles through five counties. This project is officially approved, so construction can move forward, making travel smoother and safer for trucks and drivers alike. If anyone wants to challenge these decisions, they must act by February 16, 2027, or it’s a no-go!
Next: 2026-19142, 60-Day Notice of Proposed Information Collection: DS-864E, Request for Exemption From Immigrant Visa Applicant's Affidavit of Support
The Department of State wants your thoughts on a new form, DS-864E, which lets some immigrant visa applicants skip the usual financial support paperwork. This affects about 24,000 people who apply for immigrant visas and will take about an hour to complete. You’ve got until November 17, 2026, to share your feedback—no money changes yet, just a chance to shape the process!